22.05.2012 • NewsDSMBiotechnology

DSM Invests in New R&D Facilities in the Netherlands

DSM is going to invest approximately €100 million in three new R&D facilities in Delft and Sittard-Geleen (both in the Netherlands) over the next two years.

The investment in Delft concerns a new laboratory for biotechnological research as well as a DSM contribution to the recently formed consortium for the Bioprocess Pilot Facility (BPF) for bio-research.

In Sittard-Geleen a new materials sciences research building will be realized on the Chemelot Campus.

The laboratories in Delft and Sittard-Geleen, where some 700 researchers will be working, are expected to open their doors in 2014. .

 

 

 

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.